OHE Publications

OHE releases a number of publications throughout the year, authored by OHE team members and/or outside experts. All are free for download as pdf files; hard copies of some publications are available upon request.

A description of the OHE publications categories.


Karlsberg Schaffer, S., Cubi-Molla, P., Devlin, N. and Towse, A.

Consulting Report
April 2016

This report details the views of a selection of experts in the fields of health and welfare economics on the cost-effectiveness threshold used by the National Institute for Health and Care Excellence (NICE) to decide which new medicines to recommend for use in the NHS, and the direction of future research in this area.

O'Neill, P. and Zamora, B.

Consulting Report
February 2016
The objective of this OHE Consulting Report was to outline trends in Scottish Medicines Committee (SMC) advice decisions for medicines for the period October 2009 to September 2015. This report was initiated and funded by Pfizer Ltd. It specifically considers whether there were changes in the trends due to the adoption of new policies by the SMC, namely the increased use of modifiers when assessing cost-effectiveness (e.g.

Cole, A., Garrison, L., Mestre-Ferrandiz, J. and Towse, A.

Consulting Report
November 2015

The objective of this OHE Consulting Report was to understand and develop a view on the core principles that should govern how Real-World Data (RWD) is accessed or generated, and used credibly to produce or generate Real-World Evidence (RWE), thereby working toward a set of “international standards”.

O'Neill, P. and Sussex, J.

Consulting Report
May 2015

The OHE undertook an analysis of the uptake of medicines in 13 high income countries. The UK perspective on this was published in November 2014 by the ABPI. OHE has been commissioned by LIF, the trade association of the pharmaceutical industry in Sweden, to reanalyse the international comparison of medicines uptake from the Swedish perspective; and the results are available here and on LIF’s website.

Rejon-Parrilla, J.C., Garau, M. and Sussex, J.

Consulting Report
September 2014

Obstructive sleep apnoea (OSA) is the temporary cessation of breathing during sleep because of a narrowing or closure of the pharyngeal airway. Untreated OSA can result in daytime sleepiness that affects cognitive function, mood and quality of life and can increase the risks of road traffic, work-related accidents and cardiovascular disease and strokes.

Lewis, F., Karlsberg Schaffer, S., Sussex, J., O'Neill, P. and Cockcroft, L.

Consulting Report
June 2014

Alzheimer’s Research UK commissioned OHE Consulting to model the incidence and cost of dementia in the UK and the potential impact of better treatment. The analyses estimate the extent of the substantial reductions in health and social care costs that are possible to 2050.

Rejon-Parrilla, J.C., Hernandez-Villafuerte, K., Shah, K., Mestre-Ferrandiz, J., Garrison, L. and Towse, A.

Consulting Report
May 2014

This report examines the importance and history of HTA evaluations for additional uses for cancer drugs after their initial approval. Included are the ten cancer drugs approved by the EMA during 2003–2005. Decisions by France’s HAS, NICE and Aetna in the US are analysed.